Literature DB >> 7692813

The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase.

J E Wilson1, J L Martin, K Borroto-Esoda, S Hopkins, G Painter, D C Liotta, P A Furman.   

Abstract

The (-) enantiomer of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine is a potent inhibitor of human immunodeficiency virus type 1 in vitro. The 5'-triphosphates of the (-) and (+) enantiomers equally inhibited the production of full-length minus-strand DNA in an endogenous reverse transcriptase reaction, each competitively inhibited DNA synthesis, and each was used as a chain-terminating substrate.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7692813      PMCID： PMC188052          DOI： 10.1128/AAC.37.8.1720

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

2.  Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.

Authors:  E L White; W B Parker; L J Macy; S C Shaddix; G McCaleb; J A Secrist; R Vince; W M Shannon
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

3.  Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.

Authors:  J E Reardon; W H Miller
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

4.  Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.

Authors:  H Soudeyns; X I Yao; Q Gao; B Belleau; J L Kraus; N Nguyen-Ba; B Spira; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

5.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity.

Authors:  W H Miller; S M Daluge; E P Garvey; S Hopkins; J E Reardon; F L Boyd; R L Miller
Journal:  J Biol Chem       Date:  1992-10-15       Impact factor: 5.157

7.  Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.

Authors:  G J Hart; D C Orr; C R Penn; H T Figueiredo; N M Gray; R E Boehme; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  R F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; M St Clair; J Wilson; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Biochemical analysis of human immunodeficiency virus-1 reverse transcriptase containing a mutation at position lysine 263.

Authors:  J L Martin; J E Wilson; E S Furfine; S E Hopkins; P A Furman
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157
View more
  9 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Stereochemical control of DNA biosynthesis.

Authors:  V V Sosunov; F Santamaria; L S Victorova; G Gosselin; B Rayner; A A Krayevsky
Journal:  Nucleic Acids Res       Date:  2000-03-01       Impact factor: 16.971

4.  Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.

Authors:  I Fourel; J M Cullen; J Saputelli; C E Aldrich; P Schaffer; D R Averett; J Pugh; W S Mason
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.

Authors:  M T Paff; D R Averett; K L Prus; W H Miller; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs.

Authors:  A Faraj; L A Agrofoglio; J K Wakefield; S McPherson; C D Morrow; G Gosselin; C Mathe; J L Imbach; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

7.  Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.

Authors:  A Severini; X Y Liu; J S Wilson; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

8.  Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Authors:  Rajith K R Rajoli; David J Back; Steve Rannard; Caren L Freel Meyers; Charles Flexner; Andrew Owen; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

9.  Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies.

Authors:  James J Hobson; Amer Al-Khouja; Paul Curley; David Meyers; Charles Flexner; Marco Siccardi; Andrew Owen; Caren Freel Meyers; Steve P Rannard
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.